QualityStocksNewsBreaks Archives - Page 808 of 1497

MondayMar 22, 2021 10:40 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Enters Strategic Drug Development Agreement with Catalent Inc. (NYSE: CTLT)

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced its entry into a drug development agreement with Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. According to the update, Cybin will be applying Catalent’s proprietary Zydis(R) orally disintegrating tablet (“ODT”) technology for the delivery of its novel deuterated tryptamine (“CYB003”), a potential therapy for treatment-resistant psychiatric disorders. “We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of…

MondayMar 22, 2021 10:18 am

QualityStocksNewsBreaks – Grapefruit USA Inc. (GPFT) Announces Increased Bioavailabilty for Flagship THC/CBD-Infused Cream

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed California-based cannabis company, has reached another technological milestone in the proprietary manufacturing process for its patented, disruptive Hourglass(TM) time-release THC+ cannabinoid delivery cream. In the announcement, the company noted that continued research and analysis of the manufacturing process have led to a substantial reduction in the size of the cream’s THC/CBD-infused particles. The mean particle size now measures 8.2 microns compared to previous samples, which averaged 33.1 and 29.9 microns. The company consistently analyzes the process with the intent of reducing the size of the infused particles, which leads to an increased…

MondayMar 22, 2021 10:05 am

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial,” said James Sapirstein, president, CEO and chairman of AzurRx. “Based on the very encouraging clinical results…

MondayMar 22, 2021 9:51 am

QualityStocksNewsBreaks – Knightscope K5 Deployed to Assist in Protection of California Casino

Knightscope, an advanced security technology company that builds fully autonomous security robots that deter, detect and report, has reported that it has completed another new deployment. According to the announcement, the company’s robotics are now at work in Santa Ynez, California, as the newest member of the Chumash Casino security team. A Knightscope K5 will be assisting in the protection of Chumash’s 115,000-square-foot casino, which is part of a AAA four-diamond-rated hotel that offers 320 rooms and 58 suites. “The watchful K5 will patrol the five-story resort parking structure to help keep visitors, staff and their vehicles safe,” the announcement…

MondayMar 22, 2021 9:24 am

QualityStocksNewsBreaks – Rritual Superfoods Inc. (CSE: RSF) Provides Update on Manufacturing Run, Plans to Launch Elixirs

Rritual Superfoods (CSE: RSF) (CSE: RSF.WT), a functional superfood company that creates plant-based elixirs that support immunity, focus and relaxation, has announced the successful completion of its second full-scale manufacturing run; the company also announced plans to start its third full-scale manufacturing run early next month. The announcement comes as Rritual provides an update on the anticipated launch of its plant-based superfood elixirs in the United States. In the announcement, the company noted that the second commercial scale manufacturing run was approximately 50% larger than its initial production run. The planned April run is expected to be 200% larger than the current manufacturing run,…

FridayMar 19, 2021 3:35 pm

QualityStocksNewsBreaks – RYAH Group Inc. Provides Digital Approach to Positively Impact Future Medical Treatments

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on the developments. “The patient controls the process, and the instruments that collect digital data remain anonymous. When patient feedback is optimized, medical trials and studies can move into remote solution zones… RYAH is focused on…

FridayMar 19, 2021 2:57 pm

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Aims to Supply up to 50% of US Rare Earth Demand

Energy Fuels (NYSE American: UUUU) (TSX: EFR) expects to commence commercial production of rare earth elements (“REE”) in 2021 and is focused on supplying up to 50% of U.S. rare earth demand contained in a mixed REE concentrate over the next few years. The company set out to penetrate the REE market in April 2020 “to complement its core uranium product lines,” reads an article about UUUU’s growth. “Since the announcement of the expansion into REEs, the company has made significant strides, quickly becoming an emerging player in the space.” This growth is thanks to existing momentum. “After the initial…

FridayMar 19, 2021 2:13 pm

QualityStocksNewsBreaks – Ideanomics Inc. (NASDAQ: IDEX) Targets New Investments and Acquisitions

Ideanomics (NASDAQ: IDEX), a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products, is eying expansion through acquisitions and new investments. “The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months,” reads an article on why Ideanomics is “one to watch.” “This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (‘WAVE’) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused…

FridayMar 19, 2021 1:13 pm

QualityStocksNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s Test Identifies Acute COVID-19 Infection with High Sensitivity, Specificity

United Medical Equipment (“UME,” “UMEBSNI”) has made significant progress in helping the world curb the spread of COVID-19. An article on United Medical’s successes reads, “As the world attempts to control this pandemic, it is essential to quickly identify who is infected and who has already been infected. Antibody testing determines whether or not a patient has had COVID-19 in the past, while antigen testing determines whether or not a patient currently has COVID-19… Antibody tests have limited use in detection but help to determine the accurate case numbers and research into immunity.” On the other hand, antigen rapid tests…

FridayMar 19, 2021 11:58 am

QualityStocksNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering. For more information about the company, visit www.BioPathHoldings.com About Bio-Path Holdings Inc. Bio-Path Holdings is a biotechnology…

Site Search

Company Search

Category: QualityStocksNewsBreaks